Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "randomized-controlled-trial"

23 News Found

First procedure in India performed with Medtronic's Intellis spinal cord stimulator
Medical Device | February 14, 2022

First procedure in India performed with Medtronic's Intellis spinal cord stimulator

The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator

Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx
Digitisation | August 11, 2021

Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx

OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.

Eagle Pharmaceuticals announces licensing agreement for Landiolol
Biotech | August 10, 2021

Eagle Pharmaceuticals announces licensing agreement for Landiolol

Deal signed with AOP Orphan for US commercial rights

Latest Stories

Apollo launches its 76th hospital, boosts tech-led healthcare in India

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Concept Medical unveils promising 3-year data for sirolimus balloon therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Director Bioprocessing–IMEA, Avantor
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
Saurav Kasera Founder, CLIRNET

Packaging